Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 1998

View Archived Issues

Allelix: Q3 1998 highlights

Exelon demonstrates robust effects on cognitive function in Alzheimer's disease patients

Sugen reaches milestone in collaborative agreement with Allergan

Oral aciclovir therapy reduces recurrence of herpes infection of the eye

Gene screening technology developed at Harvard Medical School licensed to Versicor

Molecular Biosystems: Q1 fiscal 1999 highlights

Single-antigen pertussis vaccine approved by FDA

Duramed receives FDA approval for hydroxyurea capsules

A significant portion of heart attack patients still do not receive proper medication

Negative interaction reported: cimetidine prolongs clarithromycin absorption

FluMist protects against influenza infection in second year of two-year study

Incel evaluated in phase II trials for the treatment of prostate cancer

Icos: Q2 1998 highlights

Roberts receives permission to launch Agrylin in Israel

Abbott discloses new antibacterial macrolides

New antiasthmatic PDE IV inhibitors revealed by Celltech

RPR reports discovery of antitumor taxoids

VivoRx discloses bifunctional paclitaxel derivatives

Searle presents new HIV protease inhibitor series

Latvian researchers discover potential new treatment for heart failure

PST-2744, an Na+/K+-ATPase inhibitor for heart failure with improved safety over digitalis

Proton pump inhibitor IY-81149 is active in models of acute and chronic gastric ulcers

Promising new antipsychotic agent in active development at Gedeon Richter

Japanese investigators study antinociceptive dynorphin analogue

European Commission approves Xenical for marketing in member countries

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...